Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6207211 | 0.84 | BCHE (0.37) | KDM4ERAB9A | |
| SCHEMBL6207402 | 0.80 | AVPR1A (0.33) | — | |
| SCHEMBL6208052 | 0.80 | HRH3 (0.34) | CYP3A4 | |
| SCHEMBL6206922 | 0.80 | BCHE (0.37) | KDM4EALDH1A1CYP3A4 | |
| SCHEMBL6230497 | 0.79 | KCNH2 (0.38) | KDM4EALDH1A1CYP3A4 | |
| SCHEMBL6404616 | 0.79 | BCHE (0.37) | MAPT | |
| SCHEMBL6206805 | 0.77 | BCHE (0.39) | ALDH1A1MAPTLMNA | |
| SCHEMBL6207452 | 0.76 | — | — | |
| SCHEMBL6208348 | 0.75 | EEF2K (0.37) | KDM4EALDH1A1MAPTPOLBCYP3A4 | |
| SCHEMBL6205424 | 0.75 | ACHE (0.56) | GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578736-A1 | MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL-PHENYLAMINE DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-09-28 | — | — | EP | claimed |
| US-6881789-B2 | Polyubiquitin based hydrogel and uses thereof | VIRIDIS BIOTECH INC. (CA) | 2005-04-19 | — | — | US | claimed |
| US-20050004186-A1 | MEK inhibiting compounds | PFIZER INC | 2005-01-06 | — | — | US | claimed |
| WO-2004056789-A1 | MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL PHENYLAMINE DERIVATES | WARNER-LAMBERT COMPANY LLC (US) | 2004-07-08 | — | — | WO | claimed |
| US-20030114724-A1 | Polyubiquitin based hydrogel and uses thereof | VIRIDIS BIOTECH INC. (CA) | 2003-06-19 | — | — | US | claimed |
| EP-1284992-A2 | POLYUBIQUITIN BASED HYDROGEL AND USES THEREOF | Viridis Biotech Inc. (CA) | 2003-02-26 | — | — | EP | claimed |
| WO-2001091814-A2 | POLYUBIQUITIN BASED HYDROGEL AND USES THEREOF | VIRIDIS BIOTECH INC. (CA) | 2001-12-06 | — | — | WO | claimed |
| US-20050004186-A1 | MEK inhibiting compounds | PFIZER INC | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004186-A1 | MEK inhibiting compounds | MAPK1, MAP3K1, MAPK3 | KDM4E 759/4885RAB9A 1822/4885EPHX2 847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.